LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
Hepion Pharmaceuticals Inc.
Headquarters:
Edison, NJ, United States of America
Website:
https://hepionpharma.com/
Year Founded:
2013
Status:
Public
Industry Sector:
HealthTechnology
CEO:
John Patrick Brancaccio, CPA
Number Of Employees:
22
Enterprise Value:
$-16,308
PE Ratio:
-0.01
Exchange/Ticker 1:
NASDAQ:HEPA
Exchange/Ticker 2:
N/A
Latest Market Cap:
$518,200
BioCentury
|
May 22, 2023
Deals
May 22 Quick Takes: Ironwood building GI franchise via $1B VectivBio acquisition
Plus: Krystal raises $160M PIPE and updates from Avrobio-Novartis, Avidity, BMS, Hepion, Rain, Blueprint
Read More
BioCentury
|
Aug 12, 2017
Product Development
HBV test kitchen
How far industry is from assembling a functional cure in HBV
Read More
BioCentury
|
Apr 28, 2017
Clinical News
Tenofovir exalidex: Interim Ph IIa data
Read More
BioCentury
|
Apr 27, 2017
Financial News
ContraVir completes follow-on
Read More
Items per page:
10
1 - 4 of 4